Acknowledgement The authors express their gratitude to Prof. T. Okamoto, Faculty of Pharmaceutical Sciences, University of Tokyo, and to Dr. Y. Kawazoe, National Cancer Center Research Institute, for their valuable discussions.

Shizuoka College of Pharmacy,
160 Oshika, Shizuoka

Received March 14, 1969

TAKUO KOSUGE
HIROSHI ZENDA
HIROYUKI SAWANISHI
YOSHINORI SUZUKI

[Chem. Pharm. Bull.
17(10)2181-2183(1969)]

UDC 547.833.5.07.04

Further Evidence for Formation of 4-Nitrosoquinoline 1-Oxide

In connection with carcinogenic and other biological activities of 4-hydroxyaminoquinoline 1-oxide (4-HAQO),¹⁾ it has been predicted in the previous paper²⁾ that 4-nitrosoquinoline 1-oxide (4-NOQO) would have been produced as an intermediate in oxidation of 4-HAQO with oxygen in the air, since in a moment right after the addition of base to the alcoholic solution of 4-HAQO the reaction mixture showed deep green color.

4-NOQO is an important compound to elucidate the relationship between carcinogenic activity and chemical structure, because 4-NOQO is the intermediate between 4-nitroquinoline 1-oxide (4-NQO) and 4-HAQO, both of which have strong carcinogenic activities. Many attempts, like reduction of 4-NQO or oxidation of 4-HAQO, have been made to synthesize 4-NOQO by many researchers, but no one has ever succeeded in obtaining the compound. The present communication is concerned with further evidences for formation of 4-NOQO in oxidation of 4-HAQO in an alkaline solution with oxygen in the air.

A solution of 4-HAQO in 0.1% NaOH aq. soln. covered with approximately same amounts of chloroform, was vigorously stirred at room temperature for an hour. The chloroform layer was subjected to chromatography on alumina, and 4-nitroquinoline 1-oxide (I), mp 153° (3% yield), 4,4'-azoquinoline 1,1'-dioxide (II), mp 260° (1.3% yield), Mass Spectrum m/e : 316 (M^+), and an unknown compound (III),³⁾ mp >360° (20% yield), $C_{18}H_{10}O_3N_4$. UV

Chart 1

- 1) a) H. Endo and F. Kume, *Naturwissenschaften*, **50**, 525 (1963); *Gann*, **54**, 443 (1963); b) Y. Shirasu and A. Ohta, *ibid.*, **54**, 221 (1963); c) C. Nagata, N. Kataoka, A. Imamura, Y. Kawazoe and G. Chihara, *ibid.*, **57**, 323 (1966); d) Y. Kawazoe and M. Tachibana, *Chem. Pharm. Bull.* (Tokyo), **15**, 1 (1967); e) N. Kataoka, S. Shibata, A. Imamura, Y. Kawazoe, G. Chihara and C. Nagata, *ibid.*, **15**, 220 (1967); f) Y. Kawazoe, M. Tachibana, A. Aoki and W. Nakahara, *Biochem. Pharmacol.*, **16**, 631 (1967); g) M. Hozumi, S. Inuzuka, and T. Sugimura, *Cancer Res.*, **27**, 1378 (1967); h) T. Okano and K. Uekama, *Chem. Pharm. Bull.* (Tokyo), **16**, 1411 (1968).
- 2) T. Kosuge and M. Yokota, *Yakugaku Zasshi*, **85**, 69 (1965).
- 3) We have isolated the same compound as III in the previous work (Ref. 2). And the structure have been proposed as 4,4'-azoxyquinoline 1,1'-dioxide ($C_{18}H_{12}O_3N_4$), since it was identified with one of the reaction products of 4-HAQO and Fehling's solution (E. Ochiai, A. Ohta and H. Nomura, *Chem. Pharm. Bull.* (Tokyo), **5**, 310 (1957).

$\lambda_{\text{max}}^{\text{CHCl}_3}$ $m\mu$ (ϵ): 270 (67100), 342 (24500), 410 (28300) were obtained. The structure of III will be discussed in the following paper.

Addition of an oxygen donar such as *p*-nitrobenzoic acid, 3,5-dinitrobenzoic acid, or 4-hydroxyquinoline 1-oxide to the reaction mixture resulted in apparent increases of the yield of 4-NQO, while the formation of 4-NQO was completely inhibited by addition of ascorbic acid or hydroxylamine (Table I, and II).

TABLE I. Results of Addition of Oxygen Donars

Oxygen donar	Yield of 4-NQO (%)	Oxygen donar	Yield of 4-NQO (%)
None	2.7	3,5-Dinitrobenzoic acid	5.2
<i>p</i> -Nitrobenzoic acid	8.9	4-Hydroxyquinoline 1-oxide	8.9

TABLE II. Results of Addition of Inhibitors

Inhibitor	Mole ratio for 4-HAQO	Yield (%)		
		4-NQO	Azo-comp.	III
None	none	2.7	1.3	20.0
Ascorbic acid	1	0.2	0.3	8.9
Ascorbic acid	2	0	0	0.3
Hydroxylamine	2	0	0.5	2.8

It seemed a reasonable explanation for the results that the addition of an oxygen donar promoted formation of free radical of 4-HAQO and further oxidation, while the addition of ascorbic acid would inhibit formation of the radical as already reported by the research groups¹⁰⁾ of National Cancer center of Japan. And hydroxylamine would react with an intermediate, probably 4-nitrosoquinoline 1-oxide, to produce diazonium compound, resulting in preventing further proceeding of the reaction to produce 4-NQO.

To confirm the assumption of diazonium compound formation, the reaction was carried out in the presence of both hydroxylamine and 2-naphthol to give deep violet needles (IV), mp 234°. UV $\lambda_{\text{max}}^{\text{MeOH}}$ $m\mu$ (ϵ): 217 (61500), 268 (15100), 515 (24400) in 1% yield. IV was proved to be identical with an authentic sample⁴⁾ of 4-(2-hydroxynaphthylazo)quinoline 1-oxide prepared by a diazo-coupling reaction of 4-aminoquinoline 1-oxide and 2-naphthol.

The isolation of IV indicates that the diazonium compound is produced as the intermediate, namely it is a fixed evidence for the formation of 4-NOQO. Besides, the isolation of 4-NQO is also a further evidence for the formation of 4-NOQO, since any other intermediate except 4-NOQO could not be thought from 4-HAQO to 4-NQO. From the both evidences, it is

4) E. Ochiai and T. Naito, *Yakugaku Zasshi*, **64**, 206 (1944).

confirmed that 4-NOQO was formed by oxidation of 4-HAQO with oxygen in basic solution. But it would be probably unable to isolate 4-NOQO as a species stable enough for application to biological tests.

Acknowledgement The authors express their gratitude to Prof. T. Okamoto, Faculty of Pharmaceutical Sciences, University of Tokyo and Dr. Y. Kawazoe, National Cancer Center Research Institute, for their valuable discussions.

Shizuoka College of Pharmacy,
160 Oshika, Shizuoka

Received March 14, 1969

TAKUO KOSUGE
HIROSHI ZENDA
MASAMI YOKOTA
HIROYUKI SAWANISHI
YOSHINORI SUZUKI

[Chem. Pharm. Bull.]
[17(10)2183—2185(1969)]

UDC 615.322 : 582.938 : 547.918.02

On the Structure of Glycoside G and K of Bei-Wujiapi

As we reported in the previous papers,^{1,2)} *n*-BuOH soluble fraction of MeOH extracts of Chinese crude drug, Bei-Wujiapi (cortex of *Periploca sepium* BGE. (Asclepiadaceae)), was revealed to contain many glycosidic substances (A—N) by TLC.³⁾

The mixture of glycosides was repeatedly purified by column chromatography affording three crystalline glycosides, tentatively named glycoside G (0.02% from dried material), glycoside H₁ (0.07%) and glycoside K (0.005%).

Glycoside G (I), C₃₆H₅₆O₁₃, mp 232—233°, colorless needles from AcOEt saturated with H₂O, $[\alpha]_D^{19} +30.2^\circ$ ($c=0.99$, EtOH), infrared (IR) $\nu_{\max}^{\text{KBr}}$ cm⁻¹: 3400, 1750, was acetylated with acetic anhydride and pyridine to give a tetraacetate, C₄₄H₆₄O₁₇, mp 198°, colorless needles from EtOH-*n*-hexane, $[\alpha]_D^{19} +17.8^\circ$ ($c=0.34$, EtOH). IR $\nu_{\max}^{\text{KBr}}$ cm⁻¹: 3500, 1750 (broad), 1235. Acid hydrolysis of I with both Kiliani mixture⁴⁾ and 0.05N H₂SO₄, yielded periplogenin,⁵⁾ D-cymarose, D-glucose, and periplobiose.⁶⁾ Enzymatic hydrolysis of I with taka-diastase-A gave D-glucose and product-GE (II), C₃₀H₄₆O₈, mp 146°/208° (double melting point), colorless needles from dil. EtOH, $[\alpha]_D^{19} +26.41^\circ$ ($c=0.92$, 95% EtOH), IR $\nu_{\max}^{\text{KBr}}$ cm⁻¹: 3400, 1750 which was identified as periplocymarin^{5b)} (III) by the mixed fusion and the comparison of TLC and IR spectrum with the authentic sample which was given us by Prof. T. Reichstein. The direct comparison of I with periplocin⁶⁾ (IV) has not yet done, but above mentioned characters of I suggest that I must be identical with periplocin. The physical constants of I, II and III, IV are comparatively summarized in Table I.

The second crystalline glycoside-K (V), C₄₀H₆₆O₁₆, mp 240—241°, colorless needles from MeOH-AcOEt saturated with H₂O, $[\alpha]_D^{20} -27.58^\circ$ ($c=1.16$, MeOH). IR $\nu_{\max}^{\text{KBr}}$ cm⁻¹: 3400, was methylated by Hakomori's method⁷⁾ to yield nona-O-methyl glycoside K (VI), C₄₉H₈₄O₁₆.

- 1) S. Sakuma, S. Kawanishi, J. Shoji, and S. Shibata, *Chem. Pharm. Bull.* (Tokyo), **16**, 326 (1968).
- 2) J. Shoji, S. Kawanishi, S. Sakuma, H. Okino, and M. Sano, *Chem. Pharm. Bull.* (Tokyo), **16**, 2308 (1968).
- 3) T. Kawasaki, and K. Miyahara, *Chem. Pharm. Bull.* (Tokyo), **11**, 1546 (1963).
- 4) H. Kiliani, *Chem. Ber.*, **63**, 2866 (1930).
- 5) a) E. Ruppel and I. Irukovic, *J. Pharm. Belg.*, **10**, 221 (1955), b) P. Brauchli, O. Schindler, and T. Reichstein, *Helv. Chim. Acta*, **44**, 904 (1961).
- 6) A. Stoll and J. Renz, *Helv. Chim. Acta*, **22**, 1193 (1939).